IL153428A0 - Solid valsartan pharmaceutical compositions - Google Patents
Solid valsartan pharmaceutical compositionsInfo
- Publication number
- IL153428A0 IL153428A0 IL15342801A IL15342801A IL153428A0 IL 153428 A0 IL153428 A0 IL 153428A0 IL 15342801 A IL15342801 A IL 15342801A IL 15342801 A IL15342801 A IL 15342801A IL 153428 A0 IL153428 A0 IL 153428A0
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical compositions
- valsartan pharmaceutical
- solid valsartan
- solid
- compositions
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
- 229960004699 valsartan Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59968700A | 2000-06-22 | 2000-06-22 | |
| PCT/EP2001/006983 WO2001097805A2 (en) | 2000-06-22 | 2001-06-20 | Solid valsartan pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL153428A0 true IL153428A0 (en) | 2003-07-06 |
Family
ID=24400655
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15342801A IL153428A0 (en) | 2000-06-22 | 2001-06-20 | Solid valsartan pharmaceutical compositions |
| IL153428A IL153428A (en) | 2000-06-22 | 2002-12-12 | Solid Velcartan Pharmaceuticals |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL153428A IL153428A (en) | 2000-06-22 | 2002-12-12 | Solid Velcartan Pharmaceuticals |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP2072049A3 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2003535895A (cg-RX-API-DMAC7.html) |
| KR (2) | KR100659644B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN1221256C (cg-RX-API-DMAC7.html) |
| AU (2) | AU8576801A (cg-RX-API-DMAC7.html) |
| BR (1) | BR0111868A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2411882C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ20024180A3 (cg-RX-API-DMAC7.html) |
| EC (1) | ECSP024389A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1052868A1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0301390A3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL153428A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02012683A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20026123L (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ522953A (cg-RX-API-DMAC7.html) |
| PL (1) | PL358290A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2333757C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG162605A1 (cg-RX-API-DMAC7.html) |
| SK (1) | SK18062002A3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001097805A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200210359B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL143233A0 (en) * | 1998-12-23 | 2002-04-21 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| WO2003059345A1 (en) * | 2002-01-17 | 2003-07-24 | Novartis Ag | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
| KR20080083071A (ko) * | 2003-08-08 | 2008-09-12 | 아지노모토 가부시키가이샤 | 나테글리니드 함유 제제 |
| WO2006021443A2 (en) * | 2004-08-26 | 2006-03-02 | Novartis Ag | Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator |
| PL2033629T3 (pl) | 2004-12-24 | 2013-04-30 | Krka | Stała kompozycja farmaceutyczna zawierająca walsartan |
| JP2009001520A (ja) * | 2007-06-21 | 2009-01-08 | Kowa Co | ジフェンヒドラミン含有固形製剤 |
| WO2009048848A1 (en) | 2007-10-09 | 2009-04-16 | Novartis Ag | Pharmaceutical formulation of valsartan |
| WO2009059605A1 (en) * | 2007-11-08 | 2009-05-14 | University Of Copenhagen | Small scale solid state screening |
| EP2067470A1 (en) * | 2007-12-03 | 2009-06-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions containing valsartan and process for its preparation |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| CN102362865B (zh) * | 2011-10-28 | 2013-06-26 | 山东司邦得制药有限公司 | 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用 |
| WO2013098576A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan |
| WO2013098578A1 (en) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Immediate release pharmaceutical composition of valsartan hydrochlorothiazide |
| CN103599084B (zh) * | 2013-11-22 | 2018-10-30 | 威海迪素制药有限公司 | 一种降压组合物 |
| CN112826806A (zh) * | 2021-01-20 | 2021-05-25 | 海南皇隆制药股份有限公司 | 一种缬沙坦片制备方法和缬沙坦片 |
| CN112807286A (zh) * | 2021-01-20 | 2021-05-18 | 海南皇隆制药股份有限公司 | 一种缬沙坦分散片制备方法和缬沙坦分散片 |
| EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| JPH09510225A (ja) * | 1994-03-17 | 1997-10-14 | チバ−ガイギー アクチェンゲゼルシャフト | バルサルタンを用いる糖尿病性ネフロパシーの治療 |
| BR9609066A (pt) * | 1995-06-07 | 1999-01-26 | Searle & Co | Antagonista aldoesterone epoxi-esteroidal e terapia de combinação de antagonista angiotensina ii para tratamento de deficiência do coração |
| MY119312A (en) * | 1995-10-06 | 2005-05-31 | Novartis Ag | At 1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
| ES2189940T3 (es) * | 1996-02-29 | 2003-07-16 | Novartis Ag | Antagonista de receptor at1 para la estimulacion de la apoptosis. |
| IL124935A (en) * | 1996-05-20 | 2001-06-14 | Janssen Pharmaceutica Nv | Dispersible antifungal compositions comprising itraconazole with improved bioavailability |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6362371B1 (en) * | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| IL143233A0 (en) * | 1998-12-23 | 2002-04-21 | Novartis Ag | Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| US20040023840A1 (en) * | 2000-04-12 | 2004-02-05 | Marc De Gasparo | Combination of organic compounds |
-
2001
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/en not_active Ceased
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active Expired - Fee Related
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 HK HK03104842.9A patent/HK1052868A1/zh unknown
- 2001-06-20 CA CA2411882A patent/CA2411882C/en not_active Expired - Fee Related
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
- 2001-06-20 EP EP09004205A patent/EP2072049A3/en not_active Withdrawn
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active Expired - Fee Related
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 EP EP01965014A patent/EP1296677A2/en not_active Ceased
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
-
2002
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
-
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
-
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2358582B (en) | Pharmaceutical compositions | |
| HUP0300582A3 (en) | Pharmaceutical compositions | |
| AU6219601A (en) | Pharmaceutical compositions | |
| EG24357A (en) | New Pharmaceutical composition | |
| IL152659A0 (en) | Pharmaceutical composition | |
| SI1524266T1 (sl) | Farmacevtski sestavek | |
| HUP0204555A3 (en) | Pharmaceutical composition | |
| AU2001250420A1 (en) | Pharmaceutical compositions | |
| GB0009584D0 (en) | Pharmaceutical compositions | |
| IL153428A0 (en) | Solid valsartan pharmaceutical compositions | |
| HUP0400553A3 (en) | Pharmaceutical compositions | |
| AU1390002A (en) | Pharmaceutical compositions | |
| GB0008485D0 (en) | Pharmaceutical compositions | |
| GB0009613D0 (en) | Pharmaceutical compositions | |
| GB0005382D0 (en) | Pharmaceutical composition | |
| AU8254101A (en) | Medicinal compositions | |
| GB0101094D0 (en) | Pharmaceutical composition | |
| GB0002691D0 (en) | Pharmaceutical composition | |
| HU0700204D0 (en) | Pharmaceutical compositions | |
| GB0000062D0 (en) | Pharmaceutical compositions | |
| GB0001337D0 (en) | Pharmaceutical compositions | |
| GB0018321D0 (en) | Pharmaceutical compositions | |
| GB0008872D0 (en) | Pharmaceutical compositions | |
| GB0003929D0 (en) | Pharmaceutical compositions | |
| GB0031282D0 (en) | Pharmaceutical compositions |